The result of TMS-007 Phase I Clinical Trial has published on British Journal of Clinical Pharmacology

The result of TMS-007 Phase I Clinical Trial, aiming to evaluate the tolerability and safety in healthy volunteers, has published on the British Journal of Clinical Pharmacology. The full article is available at below URL.

 

Article: A first-in-human study of the anti-inflammatory profibrinolytic TMS-007, an SMTP family triprenyl phenol
URL: http://doi.org/10.1111/bcp.15651　　

 

This study was conducted at P1 Unit, Clinical Research Support Center of the University of Tokyo Hospital, as a corporate clinical trial by TMS Co., Ltd. (herein after “the Company”) with support in part by grants from Japan Science and Technology Agency and the Ministry of Education, Culture, Sports, Science and Technology. 
The tolerability and safety on intravenous administration of TMS-007 up to 360mg per adult male were confirmed in the study. The achievement enabled the Company to start and successfully concluded the Phase IIa clinical trial on patients with symptomatic ischaemic stroke.

 

For more details on Phase IIa clinical trial, please see below press release.
Biogen Announces Exercise of Option to Acquire the Investigational Drug TMS-007 for Acute Ischemic Stroke Based on Positive Phase 2a Data (May 18, 2021）